3C
MYGN icon

361 Capital’s Myriad Genetics MYGN Stock Holding History

361 Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42,821
Closed -$1.97M – 369
2018
Q3 		$1.97M Buy
42,821
+194
+0.5% +$8.63K 0.43% 61
2018
Q2 		$1.59M Buy
42,627
+1,405
+3% +$47.5K 0.36% 149
2018
Q1 		$1.22M Buy
+41,222
New +$1.39M 0.3% 209

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

361 Capital's MYGN Position: Q4 2018 in Review

361 Capital sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 42,821 shares — an estimated $1.97M sold.

361 Capital first reported a position in MYGN in Q1 2018 and held it in 3 quarters. The position peaked at $1.97M in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • 361 Capital reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • 361 Capital sold 42,821 Myriad Genetics shares in Q4 2018, an estimated $1.97M.
  • 361 Capital first reported a position in Myriad Genetics in Q1 2018 and held it in 3 quarters.
  • 361 Capital's Myriad Genetics position peaked at $1.97M in Q3 2018.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.